How and why SGLT2 inhibitors should be explored as potential treatment option in diabetic retinopathy: clinical concept and methodology.
Patients suffering from type 2 diabetes are at an increased risk of developing classical microvascular complications such as retinopathy, neuropathy, and nephropathy, which represent a significant health burden. Tight control of blood glucose, blood pressure, and serum cholesterol reduce the risk of microvascular complications but effective pharmacologically targeted treatment options for the treatment and prevention of diabetic microangiopathy are still lacking. Pharmacological inhibition of sodium glucose cotransporter 2 (SGLT2) might have the potential to directly protect against microvascular complications and could represent a potential treatment option. Randomized controlled clinical proof of concept trials are needed to investigate a potential central role of SGLT2 inhibitors in the prevention of diabetic microangiopathy and its classical clinical complications of retinopathy, neuropathy, and nephropathy.
['May|Marcus|M|https://orcid.org/0000-0002-7513-4244', 'Framke|Theodor|T|', 'Junker|Bernd|B|', 'Framme|Carsten|C|', 'Pielen|Amelie|A|', 'Schindler|Christoph|C|']
diabetic retinopathy pharmacology SGLT2 Inhibition academia diabetes mellitus diabetic macula edema methods trial design